If, on one hand, the prognosis for patients with metastatic renal cell carcinoma (mRCC) has greatly improved with immune-based combinations, on the other hand their effectiveness could theoretically lead to a decrease in the use of locoregional treatments, such as cytoreductive nephrectomy, and radiotherapy (RT). However, RT as a whole, and stereotactic ablative body RT (SABR) in particular, should be regarded as a key treatment option within the global strategy for this disease. [...]
Concurrent Stereotactic Ablative Radiotherapy and Antiangiogenic Targeted Agents: Redefining the Therapeutic Strategy
Porta, Camillo
2023-01-01
Abstract
If, on one hand, the prognosis for patients with metastatic renal cell carcinoma (mRCC) has greatly improved with immune-based combinations, on the other hand their effectiveness could theoretically lead to a decrease in the use of locoregional treatments, such as cytoreductive nephrectomy, and radiotherapy (RT). However, RT as a whole, and stereotactic ablative body RT (SABR) in particular, should be regarded as a key treatment option within the global strategy for this disease. [...]File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S2588931122001791-main.pdf
non disponibili
Descrizione: Editorial
Tipologia:
Documento in Versione Editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
205.47 kB
Formato
Adobe PDF
|
205.47 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
